Redox proteomics and platelet activation: Understanding the redox proteome to improve platelet quality for transfusion

International Journal of Molecular Sciences

Volumn 18, Issue 2, 2017, Pages

  Sonego, Giona ^a   Abonnenc, Mélanie ^a   Tissot, Jean Daniel ^a,b   Prudent, Michel ^a   Lion, Niels ^a,b  

^a Laboratoire de Recherche sur les Produits Sanguins   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Activation; Aggregation; Blood products; Phosphorylation; Platelet function; Platelets; Reactive oxygen species; Redox cysteine; Transfusion

Indexed keywords

ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CATALASE; CHEMOKINE RECEPTOR CXCR4; CHLORIDE INTRACELLULAR CHANNEL 4; COLLAGEN; CYCLOOXYGENASE 1; CYSTEINE; GLYCOPROTEIN IB ALPHA PROTEIN; HYDROGEN PEROXIDE; ION CHANNEL; MITOGEN ACTIVATED PROTEIN KINASE P38; PEPTIDES AND PROTEINS; PHOSPHOLIPASE A2; PLATELET ENDOTHELIAL AGGREGATION RECEPTOR 1; PROSTAGLANDIN H2; PROTEIN P47; PROTEIN TYROSINE PHOSPHATASE; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR 4; PROTEOME; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE; THROMBIN; THROMBOCYTE CONCENTRATE; THROMBOXANE A2; TUMOR NECROSIS FACTOR ADAPTER RECEPTOR 4; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE; ANTIOXIDANT;

ANTIOXIDANT ACTIVITY; BLOOD BANK; BLOOD TRANSFUSION; CELL ACTIVITY; CRYOPRESERVATION; FUNCTIONAL PROTEOMICS; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN OXIDATION; PROTEIN PHOSPHORYLATION; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE PRESERVATION; ANIMAL; BLOOD STORAGE; METABOLISM; PHOSPHORYLATION; PROCEDURES; PROTEOMICS; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE TRANSFUSION;

ANIMALS; ANTIOXIDANTS; BLOOD PLATELETS; BLOOD PRESERVATION; CYSTEINE; HUMANS; NADPH OXIDASE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET TRANSFUSION; PROTEOME; PROTEOMICS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 85012118942     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18020387     Document Type: Review

References (144)

1. Garraud, O. Editorial: Platelets as immune cells in physiology and immunopathology. Front. Immunol. 2015, 6, 274.
2. Rondina, M.T.; Weyrich, A.S.; Zimmerman, G.A. Platelets as cellular effectors of inflammation in vascular diseases. Circ. Res. 2013, 112, 1506–1519.
3. Holbro, A.; Infanti, L.; Sigle, J.; Buser, A. Platelet transfusion: Basic aspects. Swiss Med. Wkly. 2013, 143, 13885.
4. Hoffmeister, K.M.; Felbinger, T.W.; Falet, H.; Denis, C.V.; Bergmeier, W.; Mayadas, T.N.; von Andrian, U.H.; Wagner, D.D.; Stossel, T.P.; Hartwig, J.H. The clearance mechanism of chilled blood platelets. Cell 2003, 112, 87–97.
5. Salunkhe, V.; van der Meer, P.F.; de Korte, D.; Seghatchian, J.; Gutiérrez, L. Development of blood transfusion product pathogen reduction treatments: A review of methods, current applications and demands. Transfus. Apher. Sci. 2015, 52, 19–34.
6. Kaiser-Guignard, J.; Canellini, G.; Lion, N.; Abonnenc, M.; Osselaer, J.-C.; Tissot, J.-D. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev. 2014, 28, 235–241.
7. Prowse, C.V. Component pathogen inactivation: A critical review. Vox Sang. 2013, 104, 183–199.
8. Abonnenc, M.; Sonego, G.; Kaiser-Guignard, J.; Crettaz, D.; Prudent, M.; Tissot, J.-D.; Lion, N. In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: Psoralen-based photochemical treatment step-by-step. Blood Transfus. 2015, 13, 255–264.
9. Ignatova, A.A.; Karpova, O.V.; Trakhtman, P.E.; Rumiantsev, S.A.; Panteleev, M.A. Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution. Vox Sang. 2016, 110, 244–252.
10. Janetzko, K.; Hinz, K.; Marschner, S.; Goodrich, R.; Kluter, H. Evaluation of different preparation procedures of pathogen reduction technology mirasol(R)-treated platelets collected by plateletpheresis. Transfus. Med. Hemother. 2009, 36, 309–315.
11. Maurer-Spurej, E.; Larsen, R.; Labrie, A.; Heaton, A.; Chipperfield, K. Microparticle content of platelet concentrates is predicted by donor microparticles and is altered by production methods and stress. Transfus. Apher. Sci. 2016, 55, 35–43.
12. Kerkhoffs, J.L.H. Evaluation of platelet transfusion clinical trials-Response to Corash & Sherman. Br. J. Haematol. 2011, 153, 531–532.
13. Kerkhoffs, J.L.H.; van Putten, W.L.J.; Novotny, V.M.J.; Boekhorst, P.; Schipperus, M.R.; Zwaginga, J.J.; van Pampus, L.C.M.; de Greef, G.E.; Luten, M.; Huijgens, P. C.; et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br. J. Haematol. 2010, 150, 209–217.
14. Corash, L.; Sherman, C.D. Evaluation of platelet transfusion clinical trials. Br. J. Haematol. 2011, 153, 529–531.
15. Cazenave, J.P.; Follea, G.; Bardiaux, L.; Boiron, J.M.; Lafeuillade, B.; Debost, M.; Lioure, B.; Harousseau, J.L.; Tabrizi, R.; Cahn, J. Y.; et al. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010, 50, 2362–2375.
16. Lozano, M.; Knutson, F.; Tardivel, R.; Cid, J.; Maymo, R.M.; Lof, H.; Roddie, H.; Pelly, J.; Docherty, A.; Sherman, C.; et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br. J. Haematol. 2011, 153, 393–401.
17. Heddle, N.M.; Ness, P.M. Consort and clinical trial reporting: Room for improvement. Transfusion 2016, 56, 781–783.
18. Cook, R.J.; Heddle, N.M. Clinical trials evaluating pathogen-reduced platelet products: Methodologic issues and recommendations. Transfusion 2013, 53, 1843–1855.
19. Feys, H.B.; van Aelst, B.; Devreese, K.; Devloo, R.; Coene, J.; Vandekerckhove, P.; Compernolle, V. Oxygen removal during pathogen inactivation with riboflavin and UV light preserves protein function in plasma for transfusion. Vox Sang. 2014, 106, 307–315.
20. Johnson, L.; Marks, D. Treatment of platelet concentrates with the mirasol pathogen inactivation system modulates platelet oxidative stress and NF-B activation. Transfus. Med. Hemother. 2015, 42, 167–173.
21. Kitamura, N.; Kohtani, S.; Nakagaki, R. Molecular aspects of furocoumarin reactions: Photophysics, photochemistry, photobiology, and structural analysis. J. Photochem. Photobiol. C Photochem. Rev. 2005, 6, 168–185.
22. Cardoso, D.R.; Libardi, S.H.; Skibsted, L.H. Riboflavin as a photosensitizer. Effects on human health and food quality. Food Funct. 2012, 3, 487–502.
23. Herrling, T.; Jung, K.; Fuchs, J. Measurements of UV-generated free radicals/reactive oxygen species (ROS) in skin. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2006, 63, 840–845.
24. Abonnenc, M.; Sonego, G.; Crettaz, D.; Aliotta, A.; Prudent, M.; Tissot, J.-D.; Lion, N. In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates. Transfusion 2015, 55, 2219–2230.
25. Freedman, J.E. Oxidative stress and platelets. Arterioscler. Thromb. Vasc. Biol. 2008, 28, s11–s16.
26. Zhang, B.; Zehnder, J.L. Oxidative stress and immune thrombocytopenia. Consult. Hematol. 2013, 50, e1–e4.
27. Kim, J.H.; Bae, H.Y.; Kim, S.Y. Clinical marker of platelet hyperreactivity in diabetes mellitus. Diabetes Metab. J. 2013, 37, 423–428.
28. Pignatelli, P.; Pulcinelli, F.M.; Lenti, L.; Gazzaniga, P.P.; Violi, F. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood 1998, 91, 484–490.
29. Chakrabarti, A.; Halder, S.; Karmakar, S. Erythrocyte and platelet proteomics in hematological disorders. Proteomics Clin. Appl. 2016, 10, 403–414.
30. Circu, M.L.; Aw, T.Y. Reactive oxygen species, cellular redox systems and apoptosis. Free Radic. Biol. Med. 2010, 48, 749–762.
31. Begonja, A.J.; Gambaryan, S.; Geiger, J.; Aktas, B.; Pozgajova, M.; Nieswandt, B.; Walter, U. Platelet NAD(P)H-oxidase–generated ROS production regulates IIb3-integrin activation independent of the NO/cGMP pathway. Blood 2005, 106, 2757–2760.
32. Krötz, F.; Sohn, H.Y.; Gloe, T.; Zahler, S.; Riexinger, T.; Schiele, T.M.; Becker, B.F.; Theisen, K.; Klauss, V.; Pohl, U. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 2002, 100, 917.
33. Go, Y.-M.; Jones, D.P. The redox proteome. J. Biol. Chem. 2013, 288, 26512–26520.
34. Singh, H.; Chaudhary, R.; Ray, V. Evaluation of platelet storage lesions in platelet concentrates stored for seven days. Indian J. Med. Res. 2003, 118, 243–246.
35. Thiele, T.; Iuga, C.; Janetzky, S.; Schwertz, H.; Gesell Salazar, M.; Furll, B.; Volker, U.; Greinacher, A.; Steil, L. Early storage lesions in apheresis platelets are induced by the activation of the integrin a IIb (3) and focal adhesion signaling pathways. J. Proteom. 2012, 76, 297–315.
36. Schubert, P.; Devine, D.V. Towards targeting platelet storage lesion-related signaling pathways. Blood Transfus. 2010, 8, 69–72.
37. Prudent, M.; D’Alessandro, A.; Cazenave, J.P.; Devine, D.V.; Gachet, C.; Greinacher, A.; Lion, N.; Schubert, P.; Steil, L.; Thiele, T.; et al. Proteome changes in platelets after pathogen inactivation-An interlaboratory consensus. Transfus. Med. Rev. 2014, 28, 72–83.
38. Schubert, P.; Culibrk, B.; Karwal, S.; Goodrich, R.P.; Devine, D.V. Protein translation occurs in platelet concentrates despite riboflavin/UV light pathogen inactivation treatment. Proteomics Clin. Appl. 2016, 10, 839–850.
39. Harrison, P.; Briggs, C. Chapter 27-Platelet Counting. In Platelets, 3rd ed.; Michelson, A.D., Ed.; Elsevier: London, UK, 2013; pp. 547–557.
40. Landry, P.; Plante, I.; Ouellet, D.L.; Perron, M.P.; Rousseau, G.; Provost, P. Existence of a microRNA pathway in anucleate platelets. Nat. Struct. Mol. Biol. 2009, 16, 961–966.
41. Burkhart, J.M.; Vaudel, M.; Gambaryan, S.; Radau, S.; Walter, U.; Martens, L.; Geiger, J.; Sickmann, A.; Zahedi, R.P. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood 2012, 120, e73.
42. Marrocco, C.; D’Alessandro, A.; Girelli, G.; Zolla, L. Proteomic analysis of platelets treated with irradiation versus a commercial photochemical pathogen reduction technology. Transfusion 2013, 53, 1808–1820.
43. Prudent, M.; Crettaz, D.; Delobel, J.; Tissot, J.-D.; Lion, N. Proteomic analysis of Intercept-treated platelets. J. Proteom. 2012, 76, 316–328.
44. Hechler, B.; Ohlmann, P.; Chafey, P.; Ravanat, C.; Eckly, A.; Maurer, E.; Mangin, P.; Isola, H.; Cazenave, J.P.; Gachet, C. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation. Transfusion 2013, 53, 1187–1200.
45. Thiele, T.; Sablewski, A.; Iuga, C.; Bakchoul, T.; Bente, A.; Gorg, S.; Volker, U.; Greinacher, A.; Steil, L. Profiling alterations in platelets induced by amotosalen/UVA pathogen reduction and irradiation-A LC-ESI-MS/MS-based proteomics approach. Blood Transfus. 2012, 10, 63–70.
46. Madian, A.G.; Regnier, F.E. Detection of oxidized polypeptides. U.S. Patent 9,134,318, 15 September 2015.
47. Suzuki, Y.J.; Carini, M.; Butterfield, D.A. Protein carbonylation. Antioxid. Redox Signal. 2010, 12, 323–325.
48. Prudent, M.; Sonego, G.; Abonnenc, M.; Tissot, J.-D.; Lion, N. LC-MS/MS Analysis and comparison of oxidative damages on peptides induced by pathogen reduction technologies for platelets. J. Am. Soc. Mass Spectrom. 2014, 25, 651–661.
49. Cattaruzza, M.; Hecker, M. Protein carbonylation and decarboylation: A new twist to the complex response of vascular cells to oxidative stress. Circ. Res. 2008, 102, 273–274.
50. Wright, A.; Bubb, W. A.; Hawkins, C. L.; Davies, M. J. Singlet oxygen-mediated protein oxidation: Evidence for the formation of reactive side chain peroxides on tyrosine residues. Photochem. Photobiol. 2002, 76, 35–46.
51. Abonnenc, M.; Crettaz, D.; Marvin, L.; Grund, B.; Sonego, G.; Bardyn, M.; Tissot, J.-D.; Prudent, M.; Rochat, B.; Lion, N. Metabolomic profiling highlights oxidative damages in platelet concentrates treated for pathogen inactivation and shows protective role of urate. Metabolomics 2016, 12, 188.
52. Dalle-Donne, I.; Aldini, G.; Carini, M.; Colombo, R.; Rossi, R.; Milzani, A. Protein carbonylation, cellular dysfunction, and disease progression. J. Cell. Mol. Med. 2006, 10, 389–406.
53. Reid, S.; Johnson, L.; Woodland, N.; Marks, D.C. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling. Transfusion 2012, 52, 2094–2103.
54. Wong, C.M.; Cheema, A.K.; Zhang, L.; Suzuki, Y.J. Protein carbonylation as a novel mechanism in redox signaling. Circ. Res. 2008, 102, 310–318.
55. Májek, P.; Reicheltová, Z.; Štikarová, J.; Suttnar, J.; Sobotková, A.; Dyr, J.E. Proteome changes in platelets activated by arachidonic acid, collagen, and thrombin. Proteome Sci. 2010, 8, 1–13.
56. Alexandru, N.; Constantin, A.; Popov, D. Carbonylation of platelet proteins occurs as consequence of oxidative stress and thrombin activation, and is stimulated by ageing and type 2 diabetes. Clin. Chem. Lab. Med. 2008, 46, 528–536.
57. Bakdash, N.; Williams, M.S. Spatially distinct production of reactive oxygen species regulates platelet activation. Free Radic. Biol. Med. 2008, 45, 158–166.
58. Carrim, N.; Arthur, J.F.; Hamilton, J.R.; Gardiner, E.E.; Andrews, R.K.; Moran, N.; Berndt, M.C.; Metharom, P. Thrombin-induced reactive oxygen species generation in platelets: A novel role for protease-activated receptor 4 and GPIb. Redox Biol. 2015, 6, 640–647.
59. Carrim, N.; Walsh, T.G.; Consonni, A.; Torti, M.; Berndt, M.C.; Metharom, P. Role of focal adhesion tyrosine kinases in GPVI-dependent platelet activation and reactive oxygen species formation. PLoS ONE 2014, 9, e113679.
60. Wang, L.; Soe, N.N.; Sowden, M.; Xu, Y.; Modjeski, K.; Baskaran, P.; Kim, Y.; Smolock, E.M.; Morrell, C.N.; Berk, B.C. Cyclophilin A is an important mediator of platelet function by regulating integrin IIb 3 bidirectional signalling. Thromb. Haemost. 2014, 111, 873–882.
61. Soe, N.N.; Sowden, M.; Baskaran, P.; Smolock, E.M.; Kim, Y.; Nigro, P.; Berk, B.C. Cyclophilin A is required for angiotensin II-induced p47phox translocation to caveolae in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 2147–2153.
62. Caccese, D.; Praticò, D.; Ghiselli, A.; Natoli, S.; Pignatelli, P.; Sanguigni, V.; Iuliano, L.; Violi, F. Superoxide anion and hydroxyl radical release by collagen-induced platelet aggregation-Role of arachidonic acid metabolism. Thromb. Haemost. 2000, 83, 485–490.
63. Arthur, J.F.; Gardiner, E.E.; Kenny, D.; Andrews, R.K.; Berndt, M.C. Platelet receptor redox regulation. Platelets 2008, 19, 1–8.
64. Arthur, J.F.; Shen, Y.; Gardiner, E.E.; Coleman, L.; Murphy, D.; Kenny, D.; Andrews, R.K.; Berndt, M.C. TNF receptor-associated factor 4 (TRAF4) is a novel binding partner of glycoprotein Ib and glycoprotein VI in human platelets. J. Thromb. Haemost. 2011, 9, 163–172.
65. Arthur, J.F.; Qiao, J.; Shen, Y.; Davis, A.K.; Dunne, E.; Berndt, M.C.; Gardiner, E.E.; Andrews, R.K. ITAM receptor-mediated generation of reactive oxygen species in human platelets occurs via Syk-dependent and Syk-independent pathways. J. Thromb. Haemost. 2012, 10, 1133–1141.
66. Korbecki, J.; Baranowska-Bosiacka, I.; Gutowska, I.; Chlubek, D. The effect of reactive oxygen species on the synthesis of prostanoids from arachidonic acid. J. Physiol. Pharmacol. 2013, 64, 409–421.
67. Morel, A.; Miller, E.; Bijak, M.; Saluk, J. The increased level of COX-dependent arachidonic acid metabolism in blood platelets from secondary progressive multiple sclerosis patients. Mol. Cell. Biochem. 2016, 420, 85–94.
68. Lambeth, J.D. NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol. 2004, 4, 181–189.
69. Violi, F.; Pignatelli, P. Platelet NOX, a novel target for anti-thrombotic treatment. Thromb. Haemost. 2014, 111, 817–823.
70. Bedard, K.; Krause, K.-H. The NOX Family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol. Rev. 2007, 87, 245–313.
71. Jiang, F.; Zhang, Y.; Dusting, G.J. NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. Pharmacol. Rev. 2011, 63, 218–242.
72. Finazzi-Agrò, A.; Menichelli, A.; Persiani, M.; Biancini, G.; del Principe, D. Hydrogen peroxide release from human blood platelets. Biochim. Biophys. Acta 1982, 718, 21–25.
73. Delaney, M.K.; Kim, K.; Estevez, B.; Xu, Z.; Stojanovic-Terpo, A.; Shen, B.; Ushio-Fukai, M.; Cho, J.; Du, X. Differential roles of the NADPH-oxidase 1 and 2 in platelet activation and thrombosis. Arterioscler. Thromb. Vasc. Biol. 2016, 36, 846–854.
74. Walsh, T.G.; Berndt, M.C.; Carrim, N.; Cowman, J.; Kenny, D.; Metharom, P. The role of NOX1 and NOX2 in GPVI-dependent platelet activation and thrombus formation. Redox Biol. 2014, 2, 178–186.
75. Pignatelli, P.; Carnevale, R.; Di Santo, S.; Bartimoccia, S.; Sanguigni, V.; Lenti, L.; Finocchi, A.; Mendolicchio, L.; Soresina, A.R.; Plebani, A.; et al. Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 423–434.
76. Iuliano, L.; Praticò, D.; Ghiselli, A.; Bonavita, M.S.; Violi, F. Superoxide dismutase triggers activation of “primed” platelets. Arch. Biochem. Biophys. 1991, 289, 180–183.
77. Yun, S.-H.; Sim, E.-H.; Goh, R.-Y.; Park, J.-I.; Han, J.-Y. Platelet activation: The mechanisms and potential biomarkers. BioMed Res. Int. 2016, 2016, 9060143.
78. Sangkuhl, K.; Shuldiner, A.R.; Klein, T.E.; Altman, R.B. Platelet aggregation pathway. Pharmacogenet. Genom. 2011, 21, 516–521.
79. Dayal, S.; Wilson, K.M.; Motto, D.G.; Miller, F.J.; Chauhan, A.K.; Lentz, S.R. Hydrogen peroxide promotes aging-related platelet hyperactivation and thrombosis. Circulation 2013, 127, 1308–1316.
80. Jang, J.Y.; Min, J.H.; Chae, Y.H.; Baek, J. Y.;Wang, S.B.; Park, S.J.; Oh, G. T.; Lee, S.-H.; Ho, Y.-S.; Chang, T.-S. Reactive oxygen species play a critical role in collagen-induced platelet activation via SHP-2 oxidation. Antioxid. Redox Signal. 2014, 20, 2528–2540.
81. Zhang, P.; Du, J.; Zhao, L.; Wang, X.; Zhang, Y.; Yan, R.; Dai, J.; Liu, G.; Zhang, F.; Dai, K. The role of intraplatelet reactive oxygen species in the regulation of platelet glycoprotein Ib ectodomain shedding. Thromb. Res. 2013, 132, 696–701.
82. Brill, A.; Chauhan, A.K.; Canault, M.; Walsh, M.T.; Bergmeier, W.; Wagner, D.D. Oxidative stress activates ADAM17/TACE and induces its target receptor shedding in platelets in a p38-dependent fashion. Cardiovasc. Res. 2009, 84, 137–144.
83. Choo, H.-J.; Saafir, T.B.; Mkumba, L.; Wagner, M.B.; Jobe, S.M. Mitochondrial calcium and reactive oxygen species regulate agonist-initiated platelet phosphatidylserine exposure. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 2946–2955.
84. McStay, G.P.; Clarke, S.J.; Halestrap, A.P. Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore. Biochem. J. 2002, 367, 541–548.
85. Essex, D.W. The role of thiols and disulfides in platelet function. Antioxid. Redox Signal. 2004, 6, 736–746.
86. Yan, B.; Smith, J.W. A redox site involved in integrin activation. J. Biol. Chem. 2000, 275, 39964–39972.
87. Verhaar, R.; Dekkers, D.W.; de Cuyper, I.M.; Ginsberg, M.H.; de Korte, D.; Verhoeven, A.J. UV-C irradiation disrupts platelet surface disulfide bonds and activates the platelet integrin IIb 3. Blood 2008, 112, 4935–4939.
88. Mailloux, R.J.; Jin, X.; Willmore, W.G. Redox regulation of mitochondrial function with emphasis on cysteine oxidation reactions. Redox Biol. 2014, 2, 123–139.
89. Chung, H.S.; Wang, S.-B.; Venkatraman, V.; Murray, C.I.; van Eyk, J.E. Cysteine oxidative post-translational modifications: Emerging regulation in the cardiovascular system. Circ. Res. 2013, 112, 382–392.
90. Farah, M.E.; Amberg, D.C. Conserved actin cysteine residues are oxidative stress sensors that can regulate cell death in yeast. Mol. Biol. Cell 2007, 18, 1359–1365.
91. Van der Meer, P.F.; Bontekoe, I.J.; Daal, B.B.; de Korte, D. Riboflavin and UV light treatment of platelets: A protective effect of platelet additive solution? Transfusion 2015, 55, 1900–1908.
92. Johnson, L.; Winter, K.M.; Reid, S.; Hartkopf-Theis, T.; Marschner, S.; Goodrich, R.P.; Marks, D.C. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sang. 2011, 101, 208–214.
93. Carballal, S.; Radi, R.; Kirk, M.C.; Barnes, S.; Freeman, B.A.; Alvarez, B. Sulfenic acid formation in human serum albumin by hydrogen peroxide and peroxynitrite. Biochemistry 2003, 42, 9906–9914.
94. Jang, J.Y.; Wang, S.B.; Min, J.H.; Chae, Y.H.; Baek, J.Y.; Yu, D.-Y.; Chang, T.-S. Peroxiredoxin II is an antioxidant enzyme that negatively regulates collagen-stimulated platelet function. J. Biol. Chem. 2015, 290, 11432–11442.
95. Gupta, V.; Carroll, K.S. Sulfenic acid chemistry, detection and cellular lifetime. Biochim. Biophys. Acta 2014, 1840, 847–875.
96. Paulsen, C.E.; Carroll, K.S. Cysteine-mediated redox signaling: Chemistry, biology, and tools for discovery. Chem. Rev. 2013, 113, 4633–4679.
97. Chiarugi, P.; Cirri, P. Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trends Biochem. Sci. 2003, 28, 509–514.
98. Brennan, J.P.; Bardswell, S.C.; Burgoyne, J.R.; Fuller, W.; Schröder, E.; Wait, R.; Begum, S.; Kentish, J.C.; Eaton, P. Oxidant-induced activation of type I protein kinase A is mediated by RI subunit interprotein disulfide bond formation. J. Biol. Chem. 2006, 281, 21827–21836.
99. Fiaschi, T.; Cozzi, G.; Raugei, G.; Formigli, L.; Ramponi, G.; Chiarugi, P. Redox regulation of -actin during integrin-mediated cell adhesion. J. Biol. Chem. 2006, 281, 22983–22991.
100. Chiarugi, P.; Pani, G.; Giannoni, E.; Taddei, L.; Colavitti, R.; Raugei, G.; Symons, M.; Borrello, S.; Galeotti, T.; Ramponi, G. Reactive oxygen species as essential mediators of cell adhesion: The oxidative inhibition of a FAK tyrosine phosphatase is required for cell adhesion. J. Cell Biol. 2003, 161, 933–944.
101. Giannoni, E.; Buricchi, F.; Raugei, G.; Ramponi, G.; Chiarugi, P. Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. Mol. Cell. Biol. 2005, 25, 6391–6403.
102. Messens, J.; Collet, J.-F. Thiol-disulfide exchange in signaling: Disulfide bonds as a switch. Antioxid. Redox Signal. 2013, 18, 1594–1596.
103. Furie, B.; Flaumenhaft, R. Thiol isomerases in thrombus formation. Circ. Res. 2014, 114, 1162–1173.
104. Cho, J.; Kennedy, D.R.; Lin, L.; Huang, M.; Merrill-Skoloff, G.; Furie, B.C.; Furie, B. Protein disulfide isomerase capture during thrombus formation in vivo depends on the presence of 3 integrins. Blood 2012, 120, 647–655.
105. Janiszewski, M.; Lopes, L.R.; Carmo, A.O.; Pedro, M.A.; Brandes, R.P.; Santos, C.X.C.; Laurindo, F.R.M. Regulation of NAD(P)H oxidase by associated protein disulfide isomerase in vascular smooth muscle cells. J. Biol. Chem. 2005, 280, 40813–40819.
106. Sefton, B.M. Overview of protein phosphorylation. Curr. Protoc. Cell Biol. 2001.
107. Immler, D.; Gremm, D.; Kirsch, D.; Spengler, B.; Presek, P.; Meyer, H.E. Identification of phosphorylated proteins from thrombin-activated human platelets isolated by two-dimensional gel electrophoresis by electrospray ionization-tandem mass spectrometry (ESI-MS/MS) and liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS). Electrophoresis 1998, 19, 1015–1023.
108. Zahedi, R.P.; Lewandrowski, U.; Wiesner, J.; Wortelkamp, S.; Moebius, J.; Schütz, C.; Walter, U.; Gambaryan, S.; Sickmann, A. Phosphoproteome of resting human platelets. J. Proteome Res. 2008, 7, 526–534.
109. Zimman, A.; Titz, B.; Komisopoulou, E.; Biswas, S.; Graeber, T.G.; Podrez, E.A. Phosphoproteomic analysis of platelets activated by pro-thrombotic oxidized phospholipids and thrombin. PLoS ONE 2014, 9, e84488.
110. Van Marwijk Kooy, M.; Akkerman, J.W.N.; van Asbeck, S.; Borghuis, L.; van Prooijen, H.C. UVB radiation exposes fibrinogen binding sites on platelets by activating protein kinase C via reactive oxygen species. Br. J. Haematol. 1993, 83, 253–258.
111. Schubert, P.; Culibrk, B.; Coupland, D.; Scammell, K.; Gyongyossy-Issa, M.; Devine, D.V. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage. Transfusion 2012, 52, 397–408.
112. Schwarz, U.R.; Geiger, J.; Walter, U.; Eigenthaler, M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets definition and detection of ticlopidine/clopidogrel effects. Thromb. Haemost. 1999, 82, 1145–1152.
113. Fedor, M.; Simonova, R.; Fedorova, J.; Skornova, I.; Duraj, L.; Samos, M.; Stasko, J.; Kovar, F.; Mokan, M.; Kubisz, P. Role of VASP phosphorylation assay in monitoring the antiplatelet therapy. Acta Med. Martiniana 2013, 13, 21–26.
114. Schubert, P.; Coupland, D.; Culibrk, B.; Goodrich, R.P.; Devine, D.V. Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: Inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Transfusion 2013, 53, 3164–3173.
115. Chen, Z.; Schubert, P.; Culibrk, B.; Devine, D.V. p38MAPK is involved in apoptosis development in apheresis platelet concentrates after riboflavin and ultraviolet light treatment. Transfusion 2015, 55, 848–857.
116. Paulsen, C.E.; Truong, T.H.; Garcia, F.J.; Homann, A.; Gupta, V.; Leonard, S.E.; Carroll, K.S. Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity. Nat. Chem. Biol. 2012, 8, 57–64.
117. Yang, J.; Gupta, V.; Carroll, K.S.; Liebler, D.C. Site-specific mapping and quantification of protein S-sulfenylation in cells. Nat. Commun. 2014, 5, 4776.
118. Lion, N.; Tissot, J.-D.; Prudent, M. Is proteomics still knockin’ on the hematological door? Proteomics Clin. Appl. 2016, 10, 765–766.
119. Spinella, P.C.; Pidcoke, H.F.; Strandenes, G.; Hervig, T.; Fisher, A.; Jenkins, D.; Yazer, M.; Stubbs, J.; Murdock, A.; Sailliol, A.; et al. Whole blood for hemostatic resuscitation of major bleeding. Transfusion 2016, 56, 190–202.
120. Johnson, L.; Coorey, C.P.; Marks, D.C. The hemostatic activity of cryopreserved platelets is mediated by phosphatidylserine-expressing platelets and platelet microparticles. Transfusion 2014, 54, 1917–1926.
121. Johnson, L.; Tan, S.; Wood, B.; Davis, A.; Marks, D.C. Refrigeration and cryopreservation of platelets differentially affect platelet metabolism and function: A comparison with conventional platelet storage conditions. Transfusion 2016, 56, 1807–1818.
122. Cap, A.P. Platelet storage: A license to chill. Transfusion 2016, 56, 13–16.
123. Abonnenc, M.; Crettaz, D.; Tacchini, P.; Di Vincenzo, L.; Sonego, G.; Prudent, M.; Tissot, J.-D.; Lion, N. Antioxidant power as a quality control marker for completeness of amotosalen and ultraviolet A photochemical treatments in platelet concentrates and plasma units. Transfusion 2016, 56, 1819–1827.
124. Tacchini, P.; Lesch, A.; Neequaye, A.; Lagger, G.; Liu, J.; Cortés-Salazar, F.; Girault, H.H. Electrochemical pseudo-titration of water-soluble antioxidants. Electroanalysis 2013, 25, 922–930.
125. Olas, B.; Wachowicz, B.; Nowak, P.; Kedzierska, M.; Tomczak, A.; Stochmal, A.; Oleszek, W.; Jeziorski, A.; Piekarski, J. Studies on antioxidant properties of polyphenol-rich extract from berries of Aronia melanocarpa in blood platelets. J. Physiol. Pharmacol. 2008, 59, 823–835.
126. Manasa, K.; Vani, R. Influence of oxidative stress on stored platelets. Adv. Hematol. 2016, 2016, 4091461.
127. Olas, B.; Wachowicz, B. Resveratrol and vitamin C as antioxidants in blood platelets. Thromb. Res. 2002, 106, 143–148.
128. Sobotková, A.; Mášová-Chrastinová, L.; Suttnar, J.; Štikarová, J.; Májek, P.; Reicheltová, Z.; Kotlín, R.; Weisel, J.W.; Malý, M.; Dyr, J.E. Antioxidants change platelet responses to various stimulating events. Free Radic. Biol. Med. 2009, 47, 1707–1714.
129. Shen, M.Y.; Hsiao, G.; Liu, C.L.; Fong, T.H.; Lin, K.H.; Chou, D.S.; Sheu, J.R. Inhibitory mechanisms of resveratrol in platelet activation: Pivotal roles of p38 MAPK and NO/cyclic GMP. Br. J. Haematol. 2007, 139, 475–485.
130. The Effect of Vitamin E and carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 1994, 330, 1029–1035.
131. Acker, J.P.; Marks, D.C.; Sheffield, W.P. Quality assessment of established and emerging blood components for transfusion. J. Blood Transfus. 2016, 2016, 4860284.
132. Gerber, B.; Alberio, L.; Rochat, S.; Stenner, F.; Manz, M.G.; Buser, A.; Schanz, U.; Stussi, G. Safety and efficacy of cryopreserved autologous platelet concentrates in. Transfusion 2016, 56, 2426–2437.
133. Barnard, M.R.; MacGregor, H.; Ragno, G.; Pivacek, L.E.; Khuri, S.F.; Michelson, A.D.; Valeri, C.R. Fresh, liquid-preserved, and cryopreserved platelets: Adhesive surface receptors and membrane procoagulant activity. Transfusion 1999, 39, 880–888.
134. Italiano, J.E.; Mairuhu, A.T.; Flaumenhaft, R. Clinical relevance of microparticles from platelets and megakaryocytes. Curr. Opin. Hematol. 2010, 17, 578–584.
135. Roos, M.A.; Gennero, L.; Denysenko, T.; Reguzzi, S.; Cavallo, G.; Pescarmona, G.P.; Ponzetto, A. Microparticles in physiological and in pathological conditions. Cell Biochem. Funct. 2010, 28, 539–548.
136. Holbrook, L.-M.; Watkins, N.A.; Simmonds, A.D.; Jones, C.I.; Ouwehand, W.H.; Gibbins, J.M. Platelets release novel thiol isomerase enzymes which are recruited to the cell surface following activation. Br. J. Haematol. 2010, 148, 627–637.
137. Essex, D.W.; Li, M. Protein disulphide isomerase mediates platelet aggregation and secretion. Br. J. Haematol. 1999, 104, 448–454.
138. Reinhardt, C.; von Brühl, M.-L.; Manukyan, D.; Grahl, L.; Lorenz, M.; Altmann, B.; Dlugai, S.; Hess, S.; Konrad, I.; Orschiedt, L.; et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J. Clin. Investig. 2008, 118, 1110–1122.
139. Valeri, C.R.; Macgregor, H.; Ragno, G. Correlation between in vitro aggregation and thromboxane A2 production in fresh, liquid-preserved, and cryopreserved human platelets: Effect of agonists, pH, and plasma and saline resuspension. Transfusion 2005, 45, 596–603.
140. Rasongles, P.; Angelini-Tibert, M.F.; Simon, P.; Currie, C.; Isola, H.; Kientz, D.; Slaedts, M.; Jacquet, M.; Sundin, D.; Lin, L.; et al. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion. Transfusion 2009, 49, 1083–1091.
141. Picker, S.M. Current methods for the reduction of blood-borne pathogens: A comprehensive literature review. Blood Transfus. 2013, 11, 343–348.
142. Henschler, R.; Seifried, E.; Mufti, N. Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus. Med. Hemother. 2011, 38, 33–42.
143. Mufti, N.A.; Erickson, A.C.; North, A.K.; Hanson, D.; Sawyer, L.; Corash, L.M.; Lin, L. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010, 38, 14–19.
144. Schubert, P.; Culibrk, B.; Karwal, S.; Serrano, K.; Levin, E.; Bu, D.; Bhakta, V.; Sheffield, W.P.; Goodrich, R.P.; Devine, D.V. Whole blood treated with riboflavin and ultraviolet light: Quality assessment of all blood components produced by the buffy coat method. Transfusion 2015, 55, 815–823.